Pharmacological management of depressive disorders
نویسندگان
چکیده
منابع مشابه
Ethiopathogenesis of Depressive Disorders
Etiology of depressive disorders is still unknown. Several factors are involved in its pathophysiology such as neurotransmitters and neuroendocrine alterations, genetics, life events and their appraisal. Some of these components are strictly linked. Subjects with a family member affected by mood disorders are more prone to suffer from depressive disorders. It is also true that receiving feedbac...
متن کاملTreatment of depressive disorders.
INTRODUCTION A confusing variety of options are available for the treatment of depressive disorders. METHOD Selective literature review under consideration of current guidelines. RESULTS The treatment of depression can be divided into acute, maintenance and prophylactic phases. The basic forms of treatment are pharmacotherapy, psychotherapy, and supportive strategies. The approximately 30 a...
متن کاملPost-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management
Involuntary abnormal movements have been reported after ischaemic and haemorrhagic stroke. Post stroke movement disorders can appear as acute or delayed sequel. At the moment, for many of these disorders the knowledge of pharmacological treatment is still inadequate. Dopaminergic and GABAergic systems may be mainly involved in post-stroke movement disorders. This article provides a review on dr...
متن کاملThe effectiveness of non-pharmacological interventions in older adults with depressive disorders: A systematic review.
BACKGROUND It is widely acknowledged that mental health disorders are common in older adults and that depression is one of the most serious threats to the mental health of older adults. Although best practice guidelines point out that moderate to severe depression should be approached with pharmacotherapy together with complementary therapies, the use of antidepressant drugs in older adults has...
متن کاملA model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.
OBJECTIVE To evaluate the benefit of pharmacogenetics in antidepressant treatment. METHODS In a simulated trial 100,000 subjects in a current episode of major depressive disorder (MDD) received citalopram or bupropion based on the clinician's decision (algorithm A) or following indications from 5-HTTLPR genetic testing (algorithm B), which effect size of was estimated from a meta-analysis of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medicine
سال: 2016
ISSN: 1357-3039
DOI: 10.1016/j.mpmed.2016.09.004